IPP Bureau
Antengene announces commercial availability of Xpovio in China
By IPP Bureau - May 16, 2022
The drug will be available in 600 hospitals and 105 DTPs
GeneQuantum Healthcare's two bioconjugate drugs approved for clinical trials in Australia
By IPP Bureau - May 16, 2022
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor
By IPP Bureau - May 16, 2022
It is developing the drug candidate to potentially treat immunological diseases
Urologists explore the role of robotics, equity, exercise and medicine on bladder cancer
By IPP Bureau - May 16, 2022
Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
Takeda launches Adynovate for Hemophilia patients in India
By IPP Bureau - May 16, 2022
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
Biological E. reduces Corbevax price to Rs.250 a dose
By IPP Bureau - May 16, 2022
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
Bharat Rubber Works to exhibit at PharmaPack Europe 2022
By IPP Bureau - May 16, 2022
Pharmapack offers the platform that enables Bharat Rubber Works to convey its story while simultaneously demonstrating the extraordinary advancements by the company in the field of pharmaceutical packaging
AbbVie and Cugene announce collaboration in autoimmune diseases
By IPP Bureau - May 16, 2022
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
New report highlights lack of access to assistive technology
By IPP Bureau - May 16, 2022
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Tirzepatide has potential to drive weight loss market dramatically, observes GlobalData
By IPP Bureau - May 15, 2022
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Erectile dysfunction drugs help prevent death and complications due to heart disease
By IPP Bureau - May 15, 2022
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
USFDA approves novel, dual-targeted treatment for type 2 diabetes
By IPP Bureau - May 15, 2022
In clinical trials, treatment proved more effective than other therapies evaluated
KIMS Hospitals sign MoU with Dr Raj Nagarkar to set up a hospital at Nashik
By IPP Bureau - May 15, 2022
The new hospital is expected to open by March'24
Merck KGaA first quarter earnings grows on higher volumes, margins
By IPP Bureau - May 15, 2022
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Sarclisa (isatuximab) combination provides unprecedented median progression-free survival
By IPP Bureau - May 15, 2022
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
